BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gutierrez JA, Lawitz EJ, Poordad F. Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. J Viral Hepat. 2015;22:861-870. [PMID: 26083155 DOI: 10.1111/jvh.12422] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Shahid I, AlMalki WH, Hassan S, Hafeez MH. Real-world challenges for hepatitis C virus medications: a critical overview. Crit Rev Microbiol 2018;44:143-60. [PMID: 28539069 DOI: 10.1080/1040841X.2017.1329277] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
2 Montes ML, Olveira A, Ahumada A, Aldámiz T, García-samaniego J, Clemente A, Berenguer J, González-garcía J, Martín-carbonero L. Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection. AIDS 2017;31:1253-60. [DOI: 10.1097/qad.0000000000001465] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
3 Sundberg I, Lannergård A, Ramklint M, Cunningham JL. Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study. BMC Psychiatry 2018;18:157. [PMID: 29843679 DOI: 10.1186/s12888-018-1735-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
4 Babatin MA, Alghamdi AS, Albenmousa A, Alaseeri A, Aljarodi M, Albiladi H, Alsahafi A, Almugharbal M, Alothmani HS, Sanai FM. Efficacy and Safety of Simeprevir or Daclatasvir in Combination With Sofosbuvir for the Treatment of Hepatitis C Genotype 4 Infection. J Clin Gastroenterol. 2018;52:452-457. [PMID: 28767462 DOI: 10.1097/mcg.0000000000000896] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 4.7] [Reference Citation Analysis]
5 Nappi A, Perrella A, Bellopede P, Lanza A, Izzi A, Spatarella M, Sbreglia C. Safety of new DAAs for chronic HCV infection in a real life experience: role of a surveillance network based on clinician and hospital pharmacist. Infect Agent Cancer 2017;12:12. [PMID: 28191032 DOI: 10.1186/s13027-017-0119-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
6 Li YH, Wu ZY, Tang S, Zhang X, Wang YX, Jiang JD, Peng ZG, Song DQ. Evolution of matrinic ethanol derivatives as anti-HCV agents from matrine skeleton. Bioorg Med Chem Lett. 2017;27:1962-1966. [PMID: 28320615 DOI: 10.1016/j.bmcl.2017.03.025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
7 Helal GK, Gad MA, Abd-Ellah MF, Eid MS. Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients. J Med Virol 2016;88:2170-8. [PMID: 27183377 DOI: 10.1002/jmv.24575] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
8 Kurt Yilmaz N, Swanstrom R, Schiffer CA. Improving Viral Protease Inhibitors to Counter Drug Resistance. Trends Microbiol 2016;24:547-57. [PMID: 27090931 DOI: 10.1016/j.tim.2016.03.010] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 8.7] [Reference Citation Analysis]
9 Fabrizi F, Martin P, Messa P. New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant. Kidney Int. 2016;89:988-994. [PMID: 27083277 DOI: 10.1016/j.kint.2016.01.011] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
10 Valutite D, Ostankova Y, Semenov A, Lyalina L, Totolian A. Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C. Diagnostics 2022;12:1054. [DOI: 10.3390/diagnostics12051054] [Reference Citation Analysis]
11 Arai T, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Itokawa N, Kondo C, Mikami S, Asano T, Chuganji Y, Matsuzaki Y, Toyoda H, Kumada T, Iio E, Tanaka Y, Iwakiri K. Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease: Ombitasvir/paritaprevir/ritonavir for CHC patients with CKD. Hepatol Res 2018;48:549-55. [DOI: 10.1111/hepr.13058] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
12 Tsai MC, Lin CY, Hung CH, Lu SN, Tung SY, Chien RN, Lin CL, Wang JH, Chien-Hung C, Chang KC, Hu TH, Sheen IS. Evolution of renal function under direct-acting antivirals treatment for chronic hepatitis C: A real-world experience. J Viral Hepat 2019;26:1404-12. [PMID: 31433885 DOI: 10.1111/jvh.13193] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
13 Sato S, Moriya K, Furukawa M, Saikawa S, Namisaki T, Kitade M, Kawaratani H, Kaji K, Takaya H, Shimozato N, Sawada Y, Seki K, Kitagawa K, Akahane T, Mitoro A, Okura Y, Yamao J, Yoshiji H. Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection. Clin Mol Hepatol 2019;25:65-73. [PMID: 30798587 DOI: 10.3350/cmh.2018.0070] [Reference Citation Analysis]
14 Caudai C, Materazzi A, Saladini F, Di Giambenedetto S, Torti C, Ricciardi B, Rossetti B, Almi P, De Luca A, Zazzi M. Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy. Clin Microbiol Infect 2018;24:308.e5-8. [PMID: 28811242 DOI: 10.1016/j.cmi.2017.08.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
15 Chen B, Ye Q, Zhou K, Wang Y. Adsorption and separation of HCV particles by novel affinity aptamer-functionalized adsorbents. Journal of Chromatography B 2016;1017-1018:174-81. [DOI: 10.1016/j.jchromb.2016.03.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
16 Ambarsari CG, Hidayati EL, Hasan I, Grace A, Oswari H. Successful Treatment of Hepatitis C Virus Infection Using Direct-Acting Antiviral Agents (DAAs) in Adolescents with Kidney Transplantation: A Case Series. Int J Nephrol Renovasc Dis 2020;13:139-46. [PMID: 32606888 DOI: 10.2147/IJNRD.S248632] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Zhang Q, Wang Y, Zhai N, Song H, Li H, Yang Y, Li T, Guo X, Chi B, Niu J, Crispe IN, Su L, Tu Z. HCV core protein inhibits polarization and activity of both M1 and M2 macrophages through the TLR2 signaling pathway. Sci Rep. 2016;6:36160. [PMID: 27786268 DOI: 10.1038/srep36160] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
18 Tucker JD, Meyers K, Best J, Kaplan K, Pendse R, Fenton KA, Andrieux-Meyer I, Figueroa C, Goicochea P, Gore C, Ishizaki A, Khwairakpam G, Miller V, Mozalevskis A, Ninburg M, Ocama P, Peeling R, Walsh N, Colombo MG, Easterbrook P. The HepTestContest: a global innovation contest to identify approaches to hepatitis B and C testing. BMC Infect Dis 2017;17:701. [PMID: 29143673 DOI: 10.1186/s12879-017-2771-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
19 Socías ME, Ti L, Dong H, Shoveller J, Kerr T, Montaner J, Milloy MJ. High prevalence of willingness to use direct-acting antiviral-based regimens for hepatitis C virus (HCV) infection among HIV/HCV coinfected people who use drugs. HIV Med 2017;18:647-54. [PMID: 28294492 DOI: 10.1111/hiv.12501] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
20 Vicenti I, Falasca F, Sticchi L, Bruzzone B, Turriziani O, Zazzi M. Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients. J Clin Virol 2016;76:20-3. [PMID: 26802683 DOI: 10.1016/j.jcv.2016.01.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
21 Gentile I, Maraolo AE, Niola M, Graziano V, Borgia G, Paternoster M. Limiting the access to direct-acting antivirals against HCV: an ethical dilemma. Expert Review of Gastroenterology & Hepatology 2016;10:1227-34. [DOI: 10.1080/17474124.2016.1234375] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
22 Hu KQ, Cui W. Persistence of Circulating Hepatitis C Virus Antigens-Specific Immune Complexes in Patients with Resolved HCV Infection. Dig Dis Sci 2018;63:1237-42. [PMID: 29516328 DOI: 10.1007/s10620-018-4968-9] [Reference Citation Analysis]
23 FakhriRavari A, Malakouti M, Brady R. Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection. J Clin Transl Hepatol 2016;4:97-112. [PMID: 27350940 DOI: 10.14218/JCTH.2016.00007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
24 Buonomo AR, Scotto R, Nappa S, Arcopinto M, Salzano A, Marra AM, D'Assante R, Zappulo E, Borgia G, Gentile I. The role of curcumin in liver diseases. Arch Med Sci 2019;15:1608-20. [PMID: 31749891 DOI: 10.5114/aoms.2018.73596] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Ma L, Liu J, Wang W, Yang F, Li P, Cai S, Zhou X, Chen X, Zhuang X, Zhang H, Cao G. Direct-acting antivirals and interferon-based therapy on hepatocellular carcinoma risk in chronic hepatitis-C patients. Future Oncol. 2020;16:675-686. [PMID: 32223423 DOI: 10.2217/fon-2019-0845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Shinoda M, Ebinuma H, Itano O, Yamagishi Y, Obara H, Kitago M, Nakamoto N, Hibi T, Yagi H, Abe Y, Matsubara K, Chu PS, Wakayama Y, Taniki N, Yamaguchi A, Amemiya R, Miyake R, Mizota T, Kanai T, Kitagawa Y. Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation. Hepatol Res 2016;46:1118-28. [PMID: 26854748 DOI: 10.1111/hepr.12666] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
27 Ooka K, Lim JK. Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug Therapy. J Clin Transl Hepatol 2016;4:206-27. [PMID: 27777889 DOI: 10.14218/JCTH.2016.00017] [Reference Citation Analysis]
28 Hu KQ, Cui W, Rouster SD, Sherman KE. Hepatitis C virus antigens enzyme immunoassay for one-step diagnosis of hepatitis C virus coinfection in human immunodeficiency virus infected individuals. World J Hepatol 2019; 11(5): 442-449 [PMID: 31183004 DOI: 10.4254/wjh.v11.i5.442] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
29 Leventer-Roberts M, Hammerman A, Brufman I, Hoshen M, Braun M, Ashur Y, Lieberman N, Balicer R. Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study. PLoS One 2017;12:e0176858. [PMID: 28686590 DOI: 10.1371/journal.pone.0176858] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
30 Gray Neils ME, Pfaeffle HOI, Kulatti AT, Titova A, Lyles GS, Plotnikova Y, Zorkaltseva E, Ogarkov OB, Vitko SM, Dillingham RA, Heysell SK. A Geospatial Bibliometric Review of the HIV/AIDS Epidemic in the Russian Federation. Front Public Health 2020;8:75. [PMID: 32300580 DOI: 10.3389/fpubh.2020.00075] [Reference Citation Analysis]
31 Huang F, Marzin K, Koenen R, Kammerer KP, Strelkowa N, Elgadi M, Quinson A, Haertter S. Effect of Steady-State Faldaprevir on Pharmacokinetics of Atorvastatin or Rosuvastatin in Healthy Volunteers: A Prospective Open-Label, Fixed-Sequence Crossover Study: Faldaprevir/Atorvastatin/Rosuvastatin Interaction Study. The Journal of Clinical Pharmacology 2017;57:1305-14. [DOI: 10.1002/jcph.931] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
32 Miotto N, Mendes LC, Zanaga LP, Goncales ES, Lazarini MS, Pedro MN, Goncales FL Jr, Stucchi RS, Vigani AG. Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors. Braz J Med Biol Res 2016;49:S0100-879X2016000700702. [PMID: 27356107 DOI: 10.1590/1414-431X20165300] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
33 Milazzo L, Lai A, Calvi E, Ronzi P, Micheli V, Binda F, Ridolfo A, Gervasoni C, Galli M, Antinori S, Sollima S. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy. HIV Med 2017;18:284-91. [DOI: 10.1111/hiv.12429] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 8.2] [Reference Citation Analysis]
34 Groessl EJ, Liu L, Sklar M, Ho SB. HCV Integrated Care: A Randomized Trial to Increase Treatment Initiation and SVR with Direct Acting Antivirals. Int J Hepatol 2017;2017:5834182. [PMID: 28819570 DOI: 10.1155/2017/5834182] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
35 Nkuize M, Sersté T, Buset M, Mulkay JP. Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective. Ther Clin Risk Manag 2016;12:861-72. [PMID: 27350749 DOI: 10.2147/TCRM.S77788] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
36 Shiha G, Soliman R, Elbasiony M, Darwish NHE, Mousa SA. Addition of Epigallocatechin Gallate 400 mg to Sofosbuvir 400 mg + Daclatisvir 60 mg With or Without Ribavirin in Treatment of Patients with Chronic Hepatitis C Improves the Safety Profile: A Pilot Study. Sci Rep 2019;9:13593. [PMID: 31537880 DOI: 10.1038/s41598-019-49973-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
37 Bastos JCS, Padilla MA, Caserta LC, Miotto N, Vigani AG, Arns CW. Hepatitis C virus: Promising discoveries and new treatments. World J Gastroenterol 2016; 22(28): 6393-6401 [PMID: 27605875 DOI: 10.3748/wjg.v22.i28.6393] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
38 Costantino A, Spada E, Equestre M, Bruni R, Tritarelli E, Coppola N, Sagnelli C, Sagnelli E, Ciccaglione AR. Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C. Virol J 2015;12:186. [PMID: 26577836 DOI: 10.1186/s12985-015-0414-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
39 Puenpatom A, Hull M, McPheeters J, Schwebke K. Disease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral Regimens. Clin Drug Investig 2017;37:687-97. [PMID: 28386819 DOI: 10.1007/s40261-017-0526-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
40 Barnett PG, Joyce VR, Lo J, Gidwani-Marszowski R, Goldhaber-Fiebert JD, Desai M, Asch SM, Holodniy M, Owens DK. Effect of Interferon-Free Regimens on Disparities in Hepatitis C Treatment of US Veterans. Value Health 2018;21:921-30. [PMID: 30098669 DOI: 10.1016/j.jval.2017.12.025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
41 Barré T, Marcellin F, Di Beo V, Delorme J, Rojas Rojas T, Mathurin P, Protopopescu C, Bailly F, Coste M, Authier N, Carrieri MP, Rolland B. Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study). Addiction 2020;115:573-82. [PMID: 31595554 DOI: 10.1111/add.14820] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
42 Hu KQ, Cui W. A highly specific and sensitive hepatitis C virus antigen enzyme immunoassay for One-step diagnosis of viremic hepatitis C virus infection. Hepatology. 2016;64:415-424. [PMID: 27273268 DOI: 10.1002/hep.28663] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
43 Zhou K, Fitzpatrick T, Walsh N, Kim JY, Chou R, Lackey M, Scott J, Lo YR, Tucker JD. Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. Lancet Infect Dis 2016;16:1409-22. [PMID: 27615026 DOI: 10.1016/S1473-3099(16)30208-0] [Cited by in Crossref: 82] [Cited by in F6Publishing: 41] [Article Influence: 13.7] [Reference Citation Analysis]
44 Yoh K, Nishikawa H, Enomoto H, Ishii A, Iwata Y, Miyamoto Y, Ishii N, Yuri Y, Hasegawa K, Nakano C, Nishimura T, Aizawa N, Sakai Y, Ikeda N, Takashima T, Takata R, Iijima H, Nishiguchi S. Predictors Associated with Increase in Skeletal Muscle Mass after Sustained Virological Response in Chronic Hepatitis C Treated with Direct Acting Antivirals. Nutrients 2017;9:E1135. [PMID: 29057827 DOI: 10.3390/nu9101135] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
45 El Kassas M, Alboraie M, Omar H, El Latif YA, Algaber MA, El Tahan A, El Halwagy H, Afify S, Elserafy M, Elsaeed K, Doss W. High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naïve and experienced chronic hepatitis C genotype 4: Real world results. J Med Virol 2019. [PMID: 30950069 DOI: 10.1002/jmv.25478] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
46 Ferreira VL, Tonin FS, Assis Jarek NA, Ramires Y, Pontarolo R. Efficacy of Interferon-Free Therapies for Chronic Hepatitis C: A Systematic Review of All Randomized Clinical Trials. Clin Drug Investig 2017;37:635-46. [PMID: 28409482 DOI: 10.1007/s40261-017-0521-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
47 Sbarigia U, Wirth D, Van Nuys K, Huber C, Brookmeyer R, Stahmeyer J, Krauth C. Economic study of the value of expanding HCV treatment capacity in Germany. BMJ Open Gastroenterol 2017;4:e000130. [PMID: 28461903 DOI: 10.1136/bmjgast-2016-000130] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
48 Lisboa Neto G, Malta FM, Gomes-gouvêa MS, Noble CF, Romano CM, Rebello Pinho JR, Silva MH, Leite AG, Piccoli LZ, Carrilho FJ, Mendes-correa MC. Characterization of clinical predictors of naturally occurring NS3/NS4A protease polymorphism in genotype 1 hepatitis C virus mono and HIV co-infected patients. J Med Virol 2017;89:2249-54. [DOI: 10.1002/jmv.24900] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
49 Douam F, Ding Q, Ploss A. Recent advances in understanding hepatitis C. F1000Res. 2016;5:pii: F1000. [PMID: 26918166 DOI: 10.12688/f1000research.7354.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
50 Miotto N, Mendes LC, Zanaga LP, Goncales ESL, Lazarini MSK, Pedro MN, Gonçales FL Jr, Stucchi RSB, Vigani AG. Predictors of early discontinuation of interferon-free direct antiviral agents in patients with hepatitis C virus and advanced liver fibrosis: results of a real-life cohort. Eur J Gastroenterol Hepatol 2017;29:1149-54. [PMID: 28800033 DOI: 10.1097/MEG.0000000000000944] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
51 Kim DY, Yoon KT, Kim W, Lee JI, Hong SH, Lee D, Jang JW, Choi JW, Kim I, Paik YH. Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea. Medicine (Baltimore) 2016;95:e3896. [PMID: 27472670 DOI: 10.1097/MD.0000000000003896] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
52 Gray E, O'Leary A, Bergin C, Cannon M, Courtney G, Crosbie O, De Gascun CF, Fanning LJ, Feeney E, Houlihan DD, Kelleher B, Lambert JS, Lee J, Mallon P, McConkey S, McCormick A, McKiernan S, McNally C, Murray F, Sheehan G, Stewart S, Walsh C, Norris S; Irish Hepatitis C Outcomes and Research Network (ICORN). Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program. Expert Rev Gastroenterol Hepatol 2017;11:593-601. [PMID: 28276815 DOI: 10.1080/17474124.2017.1292850] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
53 Fadl N, Salem TZ. Hepatitis C genotype 4: A report on resistance-associated substitutions in NS3, NS5A, and NS5B genes. Rev Med Virol 2020;30:e2120. [PMID: 32478480 DOI: 10.1002/rmv.2120] [Reference Citation Analysis]
54 Wong WCW, Lo YR, Jiang S, Peng M, Zhu S, Kidd MR, Wang XC, Chan PL, Ong JJ. Improving the hepatitis cascade: assessing hepatitis testing and its management in primary health care in China. Fam Pract 2018;35:731-7. [PMID: 29741661 DOI: 10.1093/fampra/cmy032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
55 Al-zoman NZ, Maher HM, Al-subaie A. Eco-friendly micellar electrokinetic capillary chromatographic method for the simultaneous determination of newly developed antiviral agents in pharmaceutical formulations. Journal of Liquid Chromatography & Related Technologies 2018;41:973-81. [DOI: 10.1080/10826076.2018.1538884] [Reference Citation Analysis]
56 Jimenez-Sousa MÁ, Gutiérrez-Rivas M, Álvaro-Meca A, García-Álvarez M, Harrigan PR, Fedele CG, Briz V, Vázquez-Morón S, Resino S. NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in Spain. PLoS One 2016;11:e0163197. [PMID: 27685471 DOI: 10.1371/journal.pone.0163197] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
57 Poovorawan K, Pan-Ngum W, White LJ, Soonthornworasiri N, Wilairatana P, Wasitthankasem R, Tangkijvanich P, Poovorawan Y. Estimating the Impact of Expanding Treatment Coverage and Allocation Strategies for Chronic Hepatitis C in a Direct Antiviral Agent Era. PLoS One 2016;11:e0163095. [PMID: 27631382 DOI: 10.1371/journal.pone.0163095] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
58 Kutala BK, Mouri F, Castelnau C, Bouton V, Giuily N, Boyer N, Asselah T, Marcellin P. Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort. Hepat Med 2017;9:67-73. [PMID: 29296102 DOI: 10.2147/HMER.S149578] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
59 Sanai FM, Alghamdi AS, Afghani AA, Alswat K, AlZanbagi A, Alghamdi MN, AlMousa A, Aseeri M, Assiri AM, Babatin MA. High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease. Liver Int. 2018;38:1395-1401. [PMID: 29288514 DOI: 10.1111/liv.13674] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
60 Al-Zoman NZ, Maher HM, Al-Subaie A. Simultaneous determination of newly developed antiviral agents in pharmaceutical formulations by HPLC-DAD. Chem Cent J 2017;11:1. [PMID: 28101128 DOI: 10.1186/s13065-016-0232-6] [Cited by in Crossref: 36] [Cited by in F6Publishing: 18] [Article Influence: 7.2] [Reference Citation Analysis]
61 C Pak S, Alastal Y, Khan Z, Darr U. Viral Hepatitis in South Korea. Euroasian J Hepatogastroenterol 2017;7:163-5. [PMID: 29201801 DOI: 10.5005/jp-journals-10018-1240] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]